(Updated - June 29, 2026 5:49 AM EDT)

UBS analyst Ashwani Verma upgraded Cytokinetics (NASDAQ: CYTK) from Neutral to ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE